(Total Views: 608)
Posted On: 01/29/2022 12:45:02 PM
Post# of 155844
Re: craigakess #116742
We have 200m shares. Even if they sold them all right now, that's $100m.
It's obviously true we need revenue and/or a partner, and there are debts (as with any pre-rev biotech), but money's not as tight as some posit. I certainly don't think they stopped or slowed Brazil critical trial because of money. That trial could be the quickest to generate an EUA and revenue.
It's obviously true we need revenue and/or a partner, and there are debts (as with any pre-rev biotech), but money's not as tight as some posit. I certainly don't think they stopped or slowed Brazil critical trial because of money. That trial could be the quickest to generate an EUA and revenue.
(8)
(0)
